Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GB001 Recombinant Peptide Spray in Healthy Chinese Adults
NCT05125211Phase 1Active, not recruiting
- Sponsor
- Zhejiang Echon Biopharm
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GB001 in Recurrent aphthous stomatitis (RAS) (3 arms), sponsored by Zhejiang Echon Biopharm. Primary endpoint: Incidence of adverse events. Started Aug 2022; status: active, not recruiting.
02
Drugs
GB001
03
Conditions
Recurrent aphthous stomatitis (RAS)
Beyond the preview
Go deeper on NCT05125211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125211.